Buy This Document Now

Price: $125.00

ADD TO CART

NEW!

Maxygen Profile

43 resources including:

Maxygen, Inc. (MAXY) - Financial and Strategic Analysis Review
Maxygen, Inc. 2006 Annual Report

See Full Profile >>

Document provided by...: www.globaldata.com; (Learn more...); GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.

About This Document: Maxygen, Inc. (Maxygen) is a development-stage biotechnology company dedicated to maximize the potential of protein-based pharmaceuticals. The company is developing improved versions of protein compounds to treat serious diseases, such as neutropenia, often caused by chemotherapy treatments. Maxygen uses MolecularBreeding directed evolution technology platform, ancillary technologies, and extensive protein modification expertise for creating biosuperior proteins. The company does its R&D activities through Perseid Therapeutics LLC. Perseid Therapeutics was established as a majority-owned subsidiary of the company in september 2009.

Maxygen, Inc. Key Recent Developments

May 06, 2010 Maxygen Reports Net Loss Of $2 Million For Q1 2010
Nov 05, 2009 Maxygen Reports Net Loss Of $21.7 Million For Q3 2009
Jul 14, 2009 Maxygen Presents Positive Results From Breast Cancer Study
May 11, 2009 Maxygen Q1 2009 Net Loss Narrows
May 07, 2009 Cangene Files Bid To Develop New Drug for Acute Radiation Syndrome

This comprehensive SWOT profile of Maxygen, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brand

Stats: Type:
Acrobat PDF; Size:
324 kb; Pages:
33; Views:
12; Posted:
08/16/10

NEW!

Comprehensive Company Profile: Maxygen | Maxygen, Inc.

Financial & strategy reports, market research, agreements & more

Maxygen, Inc. (MAXY) - Financial and Strategic Analysis Review

Document Sample

Maxygen, Inc. (MAXY) - Financial and Strategic Analysis Review

Reference Code: GDPH31228FSA Publication Date: JUL 2010

515 Galveston Drive Phone +1 650 2985300 Revenue 36.4 (million USD)

Redwood City, CA Fax +1 650 3642715 Net Profit -32.40 (million USD)

94063 Website www.maxygen.com Employees 64

United States Exchange MAXY [NASDAQ] Industry Pharmaceuticals & Healthcare

Company Overview

Maxygen, Inc. (Maxygen) is a development-stage biotechnology company dedicated to maximize the potential of protein-based

pharmaceuticals. The company is developing improved versions of protein compounds to treat serious diseases, such as

neutropenia, often caused by chemotherapy treatments. Maxygen uses MolecularBreeding directed evolution technology

platform, ancillary technologies, and extensive protein modification expertise for creating biosuperior proteins. The company does

its R&D activities through Perseid Therapeutics LLC. Perseid Therapeutics was established as a majority-owned subsidiary of the

company in september 2009.

Key Executives SWOT Analysis

Name Title Maxygen, Inc., SWOT Analysis

Isaac Stein Chairman Strengths Weaknesses

James R. Sulat Chief Executive Officer

Proprietary Technologies Confined Geographic

M.R.C. Greenwood Director Presence

Louis G. Lange, M.D., Ph.D. Director Sturdy Research and

Development Activities Lack of Manufacturing Facility

Gordon Ringold Director

Source: Annual Report, Company Website, Primary and Secondary Research

GlobalData

Opportunities Threats

Share Data

Maxygen, Inc. Efficacy of MAXY-G34 Intense Competition

Share Price (USD) as on 21-Jul-2010 5.90

-0.85 Alliances and Collaborations Impact of the Financial Crisis

EPS (USD)

Market Cap (million USD) 182

Enterprise Value (million USD) 60

Source: Annual Report, Company Website, Primary and Secondary Research

Shares Outstanding (million) 31 GlobalData

Source: Annual Report, Company Website, Primary and Secondary Research

GlobalData

Financial Performance

By registering with docstoc.com you agree to our
privacy policy and terms of service

Buy This Document Now

Price: $125.00

Maxygen, Inc. (MAXY) - Financial and Strategic Analysis Review

Successfully added document to cart!

You have already registered, we just need your password.

Successfully added document to cart!

You have already registered, we just need your password.

Buy This Document Now

Price: $125.00

Maxygen, Inc. (MAXY) - Financial and Strategic Analysis Review

Also From This Publisher

Successfully added document to cart!

You have already registered, we just need your password.

Register and get access to “Maxygen, Inc. (MAXY) - Financial and Strategic Analysis Review”

Successfully added document to cart!

You have already registered, we just need your password.

Login to continue downloading: “Maxygen, Inc. (MAXY) - Financial and Strategic Analysis Review”